Nanobiotix Raises €86.1 Million in Follow-on Offering
Biotech firm Nanobiotix has raised approximately €86.1 million in a follow-on offering including pre-funded warrants, which will accelerate the development of the company's other platforms.
PARIS and CAMBRIDGE, Mass. – June 02, 2026 – Nanobiotix, a clinical-stage biotechnology company focused on cancer treatments, provided its first quarter 2026 operational and financial update. The company announced it completed a follow-on offering in May 2026, generating gross proceeds of approximately €86.1 million. In addition, the company issued pre-funded warrants to accelerate the development of its other platforms in development.
New data from Part 1 of the J&J-sponsored Phase 2 CONVERGE study, evaluating JNJ-1900 (NBTXR3), were presented. Furthermore, Nanobiotix joined the Euronext Tech Leaders Index on June 02, 2026, which recognizes Europe's leading technology companies. This inclusion highlights companies poised to shape the future of the technology sector.
Nanobiotix, whose shares are listed on Euronext Paris (NANO) and Nasdaq (NBTX), focuses on physics-based therapeutic approaches to expand treatment possibilities for patients with cancer. The company continues its research efforts aimed at improving patient outcomes.
The company's progress and financial standing provide a solid foundation for future growth and product development, particularly within its cancer therapeutic areas. This capital infusion supports the continued expansion of the company's product pipeline.